Dataset Information

Prevalence of human cystic echinococcosis in the towns of Norquinco and Ramos Mexia in Rio Negro Province, Argentina, and direct risk factors for infection.

ABSTRACT:

Background

Cystic echinococcosis (CE) is a parasitic zoonosis caused by infection with the larval stage of Echinococcus granulosus (s.l.). This study investigated the prevalence and potential risk factors associated with human CE in the towns and rural areas of Ñorquinco and Ramos Mexia, Rio Negro province, Argentina.

Methods

To detect abdominal CE cysts, we screened 892 volunteers by ultrasound and investigated potential risk factors for CE using a standardized questionnaire. Prevalence ratio (PR) with 95% confidence intervals (CI) was used to measure the association between CE and the factors investigated, applying bivariate and multivariate analyses.

Results

Abdominal CE was detected in 42/892 screened volunteers (4.7%, 95% CI 3.2-6.1), only two of whom were under 15 years of age. Thirteen (30.9%) CE cases had 25 cysts in active stages (CE1, CE2, CE3a, according to the WHO Informal Working Group on Echinococcosis [WHO-IWGE] classification). The most relevant risk factors identified in the bivariate analysis included: living in rural areas (P = 0.003), age > 40 years (P = 0.000), always drinking water from natural sources (P = 0.007), residing in rural areas during the first 5 years of life (P = 0.000) and having lived more than 20 years at the current address (P = 0.013). In the multivariate final model, the statistically significant risk factors were: frequently touching dogs (P = 0.012), residing in rural areas during the first 5 years of life (P = 0.004), smoking (P = 0.000), age > 60 years (P = 0.002) and living in rural areas (P = 0.017).

Conclusions

Our results point toward infection with CE being acquired since childhood and with constant exposure throughout life, especially in rural areas with a general environmental contamination.

SUBMITTER: Uchiumi L

PROVIDER: S-EPMC8136178 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:The Los Menucos locality in Patagonia, Argentina, bears a well-known ichnofauna mostly documented by small therapsid footprints. Within this ichnofauna, large pentadactyl footprints are also represented but to date were relatively underinvestigated. These footprints are here analyzed and discussed based on palaeobiological indications (i.e., trackmaker identification). High resolution digital photogrammetry method was performed to achieve a more objective representation of footprint three-dimensional morphologies. The footprints under study are compared with Pentasauropus from the Upper Triassic lower Elliot Formation (Stormberg Group) of the Karoo Basin (Lesotho, southern Africa). Some track features suggest a therapsid-grade synapsid as the potential trackmaker, to be sought among anomodont dicynodonts (probably Kannemeyeriiformes). While the interpretation of limb posture in the producer of Pentasauropus tracks from the Los Menucos locality agrees with those described from the dicynodont body fossil record, the autopodial posture does not completely agree. The relative distance between the impression of the digital (ungual) bases and the distal edge of the pad trace characterizing the studied tracks likely indicates a subunguligrade foot posture (i.e., standing on the last and penultimate phalanges) in static stance, but plantiportal (i.e., the whole foot skeleton and related soft tissues are weight-bearing) during the dynamics of locomotion. The reconstructed posture might have implied an arched configuration of the articulated metapodials and at least of the proximal phalanges, as well as little movement capabilities of the metapodials. Usually, a subunguligrade-plantiportal autopod has been described for gigantic animals (over six hundreds kilograms of body weight) to obtain an efficient management of body weight. Nevertheless, this kind of autopod is described here for large but not gigantic animals, as the putative trackmakers of Pentasauropus were. This attribution implies that such an autopodial structure was promoted independently from the body size in the putative trackmakers. From an evolutionary point of view, subunguligrade-plantiportal autopods not necessarily must be related with an increase in body size, but rather the increase in body size requires a subunguligrade or unguligrade, plantiportal foot. Chronostratigraphically, Pentasauropus was reported from Upper Triassic deposits of South Africa and United States, and from late Middle Triassic and Upper Triassic deposits of Argentina. Based on the stratigraphic distribution of the ichnogenus currently accepted, a Late Triassic age is here proposed for the Pentasauropus-bearing levels of the Los Menucos Group.

Project description:BackgroundHuman cystic echinococcosis (CE), caused by the larval stage of Echinococcus granulosus, with the liver as the most frequently affected organ, is known to be highly endemic in Tibetan communities of northwest Sichuan Province. Antiparasitic treatment with albendazole remains the primary choice for the great majority of patients in this resource-poor remote area, though surgery is the most common approach for CE therapy that has the potential to remove cysts and lead to complete cure. The current prospective study aimed to assess the effectiveness of community based use of cyclic albendazole treatment in Tibetan CE cases, and concurrently monitor the changes of serum specific antibody levels during treatment.Methodology/principal findingsUltrasonography was applied for diagnosis and follow-up of CE cases after cyclic albendazole treatment in Tibetan communities of Sichuan Province during 2006 to 2008, and serum specific IgG antibody levels against Echinococcus granulosus recombinant antigen B in ELISA was concurrently monitored in these cases. A total of 196 CE cases were identified by ultrasound, of which 37 (18.9%) showed evidence of spontaneous healing/involution of hepatic cyst(s) with CE4 or CE5 presentations. Of 49 enrolled CE cases for treatment follow-up, 32.7% (16) were considered to be cured based on B-ultrasound after 6 months to 30 months regular albendazole treatment, 49.0% (24) were improved, 14.3% (7) remained unchanged, and 4.1% (2) became aggravated. In general, patients with CE2 type cysts (daughter cysts present) needed a longer treatment course for cure (26.4 months), compared to cases with CE1 (univesicular cysts) (20.4 months) or CE3 type (detached cyst membrane or partial degeneration of daughter cysts) (9 months). In addition, the curative duration was longer in patients with large (>10 cm) cysts (22.3 months), compared to cases with medium (5-10 cm) cysts (17.3 months) or patients with small (<5 cm) cysts (6 months). At diagnosis, seven (53.8%) of 13 cases with CE1 type cysts without any previous intervention showed negative specific IgG antibody response to E. granulosus recombinant antigen B (rAgB). However, following 3 months to 18 months albendazole therapy, six of these 7 initially seronegative CE1 cases sero-converted to be specific IgG antibody positive, and concurrently ultrasound scan showed that cysts changed to CE3a from CE1 type in all the six CE cases. Two major profiles of serum specific IgG antibody dynamics during albendazole treatment were apparent in CE cases: (i) presenting as initial elevation followed by subsequent decline, or (ii) a persistent decline. Despite a decline, however, specific antibody levels remained positive in most improved or cured CE cases.ConclusionsThis was the first attempt to follow up community-screened cystic echinococcosis patients after albendazole therapy using ultrasonography and serology in an endemic Tibetan region. Cyclic albendazole treatment proved to be effective in the great majority of CE cases in this resource-poor area, but periodic abdominal ultrasound examination was necessary to guide appropriate treatment. Oral albendazole for over 18 months was more likely to result in CE cure. Poor drug compliance resulted in less good outcomes. Serology with recombinant antigen B could provide additional limited information about the effectiveness of albendazole in CE cases. Post-treatment positive specific IgG antibody seroconversion, in initially seronegative, CE1 patients was considered a good indication for positive therapeutic efficacy of albendazole.